Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Xuanzhu Bio, a Sihuan Novel Drug Subsidiary, Completes $116 Million Funding

publication date: Aug 24, 2020

Sihuan Pharma reported its innovative drug subsidiary, Xuanzhu Biopharma, completed a $116 million Series A round financing from SDIC. SDIC will own 18.6% of Xuanzhu, which is valued at $624 million. Sihuan said Xuanzhu is differentiated from other startups by having complete drug R&D capability along with the parent company's production and commercialization support. The company has two candidates in late-stage trials: birociclib, a CDK4/6 inhibitor for advanced breast cancer and janagliflozin, an SGLT2 inhibitor for diabetes. More details....

Stock Symbol: (HK: 0460)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.